title: Brentuximab vedotin  in systemic T-cell lymphoma.
abstract: BACKGROUND
  Brentuximab vedotin is an antibody-drug conjugate which consists of the anti-CD30 monoclonal antibody cAC10 conjugated with the cytotoxic agent monomethyl auristatin E (MMAE). Brentuximab vedotin has been approved by the US Food and Drug Administration for the treatment of relapsed or refractory Hodgkin's lymphoma (HL) and anaplastic large cell lymphoma (ALCL). The efficacy of brentuximab vedotin in other CD30(+) lymphomas is currently being investigated.
  
  
  METHODS
  In this paper, we review the currently available treatment options for systemic peripheral T-cell lymphomas (PTCL) and the role of brentuximab vedotin in relapsed or refractory ALCL. In addition, ongoing clinical trial of brentuximab vedotin in relapsed PTCL and combination therapy with other chemotherapies for initial treatment of CD30 lymphoma will also be reviewed.
  
  
  CONCLUSIONS
  Brentuximab vedotin has established its role in the treatment of relapsed or refractory HL and ALCL. In the next few years, the efficacy of this agent in other CD30(+) lymphomas will be described. The safety and efficacy of several brentuximab-based combination regimens, including use as frontline chemotherapy is under investigation.
authors.affiliation: Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. yoki@mdanderson.org
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Oki
authors.forename: Anas
authors.initials: A
authors.lastname: Younes
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D016399:Lymphoma, T-Cell / Q000188:drug therapy*; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D000079963:Brentuximab Vedotin